{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:01:28Z","timestamp":1784894488340,"version":"3.55.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oritavancin is a long-acting semisynthetic lipoglycopeptide with potent activity against a broad range of Gram-positive pathogens. Its multimodal mechanism of action and prolonged terminal half-life allow for extended dosing intervals, making it an off-label option for invasive infections requiring long-term antimicrobial exposure. However, evidence supporting its use in infective endocarditis and cardiac device\u2013related infections remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective multicentre observational study including adult patients treated with multidose oritavancin for infective endocarditis and cardiac device-related infections between 2020 and 2025. Oritavancin was administered as consolidation or as long-term suppressive therapy. Demographic, clinical, microbiological, pharmacological, and outcome data were collected. Therapeutic drug monitoring was performed, and pre-dose plasma concentrations were analysed. Clinical outcomes included clinical cure, microbiological failure, adverse events, and 30- and 90-day all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine patients were included. Oritavancin was mainly administered at 1200\u2005mg per dose, with a median dosing interval of 10\u2005days. Clinical success was achieved in 6\/9 patients (66.7%). One patient discontinued therapy due to infusion-related adverse events, and two experienced microbiological failure, both in left ventricular assist device-related infections. No 30- or 90-day mortality was observed. TDM, when performed, demonstrated persistent pre-dose plasma concentrations over several weeks, with marked interindividual variability across patients and intra-individual temporal changes over time, including drug accumulation in some cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Multidose oritavancin appears to be a promising consolidation or suppressive strategy in selected patients with complex Gram-positive endovascular infections. Prospective studies are needed to define optimal dosing regimens and the role of TDM in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag150","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:42:12Z","timestamp":1784202132000},"source":"Crossref","is-referenced-by-count":0,"title":["Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring"],"prefix":"10.1093","volume":"8","author":[{"given":"Simone","family":"Giuliano","sequence":"first","affiliation":[{"name":"Infectious Diseases Division, Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3160-0171","authenticated-orcid":false,"given":"Luca","family":"Martini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-1163","authenticated-orcid":false,"given":"Maria","family":"Merelli","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Turicchi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano Hospital , Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Angelini","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology Institute, University Hospital Friuli Centrale ASUFC , Udine 33100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ferin","sequence":"additional","affiliation":[{"name":"Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019avolio","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin\u2014ASL \u2018Citt\u00e0 di Torino\u2019 , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-8635","authenticated-orcid":false,"given":"Paolo","family":"Gaibani","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Public Health, University of Verona , Verona ,","place":["Italy"]},{"name":"Microbiology and Virology Unit, Department of Pathology, Azienda Ospedaliera Universitaria Integrata di Verona , Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-3707","authenticated-orcid":false,"given":"Marco","family":"Bongiovanni","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano Hospital , Lugano ,","place":["Switzerland"]},{"name":"Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano Hospital , ; , Lugano ,","place":["Switzerland Switzerland"]},{"name":"Department of Biomedical Sciences, University of Southern Switzerland , ; , Lugano ,","place":["Switzerland Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9625-6024","authenticated-orcid":false,"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) , Udine ,","place":["Italy"]},{"name":"Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072407084572900_dlag150-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40121-016-0103-4","article-title":"Oritavancin: a new lipoglycopeptide antibiotic in the treatment of gram-positive infections","volume":"5","author":"Brade","year":"2016","journal-title":"Infect Dis Ther"},{"key":"2026072407084572900_dlag150-B2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol Rev"},{"issue":"SUPPL. 3","key":"2026072407084572900_dlag150-B3","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: mechanism of action","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026072407084572900_dlag150-B4","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12101498","article-title":"The clinical efficacy of multidose oritavancin: a systematic review","volume":"12","author":"Baiardi","year":"2023","journal-title":"Antibiotics"},{"key":"2026072407084572900_dlag150-B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s40801-020-00188-6","article-title":"A two-dose oritavancin regimen using pharmacokinetic estimation analysis","volume":"7","author":"Rose","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"2026072407084572900_dlag150-B6","doi-asserted-by":"publisher","first-page":"ofv156","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2026072407084572900_dlag150-B7","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1093\/jac\/dkaf215","article-title":"Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?","volume":"80","author":"Turicchi","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026072407084572900_dlag150-B8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf416","article-title":"The use of oritavancin as consolidation therapy for infective endocarditis caused by Enterococcus spp","volume":"12","author":"Frondizi","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026072407084572900_dlag150-B9","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC guidelines for the management of endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"},{"key":"2026072407084572900_dlag150-B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.108111","article-title":"Medical source control with oritavancin in complicated gram-positive bacterial infections: a case series","volume":"161","author":"De Rosa","year":"2025","journal-title":"Int J Infect Dis"},{"key":"2026072407084572900_dlag150-B11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jac\/dkw451","article-title":"Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci","volume":"72","author":"Sweeney","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026072407084572900_dlag150-B12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"2026072407084572900_dlag150-B13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s40121-025-01215-1","article-title":"A comparative review of the pharmacology of dalbavancin and oritavancin for gram-positive infections: birds of a feather or apples and oranges?","volume":"14","author":"Hussein","year":"2025","journal-title":"Infect Dis Ther"},{"key":"2026072407084572900_dlag150-B14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac090","article-title":"Kimyrsa, an oritavancin-containing product: clinical study and review of properties","volume":"9","author":"Hoover","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026072407084572900_dlag150-B15"},{"key":"2026072407084572900_dlag150-B16","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1128\/AAC.50.3.994-1000.2006","article-title":"Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia","volume":"50","author":"Bhavnani","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026072407084572900_dlag150-B17","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1128\/AAC.00176-15","article-title":"Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials","volume":"59","author":"Rubino","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026072407084572900_dlag150-B18","doi-asserted-by":"publisher","DOI":"10.3390\/life13040959","article-title":"Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: narrative review and possible developments","volume":"13","author":"Lupia","year":"2023","journal-title":"Life (Basel)"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag150\/69934734\/dlag150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag150\/69934734\/dlag150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:08:53Z","timestamp":1784891333000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag150\/8741257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag150","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dlag150"}}